Regular use of analgesics is a risk factor for renal cell carcinoma by Gago-Dominguez, M et al.
Kidney cancer is a relatively rare malignancy. In the USA, there
are roughly 30 000 new cases of kidney cancer each year,
accounting for approximately 2% of all incident cancer cases diag-
nosed annually (Parker et al, 1996). Renal cell carcinoma (RCC)
accounts for 80–85% of all kidney cancers in the USA. The
remaining 15–20% of kidney cancers are mostly cancers of the
renal pelvis, which are anatomically and histologically distinct
from RCC (Devesa et al, 1990).
Chronic use of analgesics was first linked to the development of
kidney cancer through a series of case reports which documented
cancer of the renal pelvis occurring in heavy users of phenacetin
(Bengtsson et al, 1968; Mahony et al, 1977). These uncontrolled
observations were later confirmed by a number of case–control
studies conducted in diverse populations (McCredie et al, 1982;
McLaughlin et al, 1985; Jensen et al, 1989). In 1987, the
International Agency for Research on Cancer concluded that
there was sufficient evidence to name phenacetin as a human
carcinogen.
The relationship between analgesic use and RCC is less clear.
Until recently, only three case–control studies (Armstrong et al,
1976; McLaughlin et al, 1985; McCredie et al, 1988) and one
cohort study (Paganini-Hill et al, 1989) had investigated the issue.
Two of these studies (McLaughlin et al, 1985; McCredie et al,
1988) examined the relationship between phenacetin use and
RCC risk, and consistently observed a positive exposure-disease
association. Taken as a whole, the four studies were inconclusive
with respect to non-phenacetin types of analgesics. Although
human data are largely lacking, there is sufficient reason for
concern in terms of the potential carcinogenic risk of non-
phenacetin-based analgesics. Acetaminophen is a major metabo-
lite of phenacetin in humans (Brodie and Axelrod, 1949), and is
capable of inducing liver cell tumours in mice (Flaks and Flaks,
1983). Aspirin and most other non-steroidal anti-inflammatory
agents (NSAIDs) are nephrotoxic in humans and in animals
(Nanra, 1983). It is generally recognized that increased cell pro-
liferation (which follows cytotoxicity and cell necrosis) is an
important mechanism of increased cancer risk in humans
(Henderson et al, 1991). Thus, nephrotoxic agents are potential
nephrocarcinogens.
Given the public health importance of the possible
analgesic–RCC association [in 1984, just prior to the start of this
study, annual sales of analgesic drugs in the USA exceeded
1.9 billion dollars (Consumer Expenditure Study, 1985)], we
initiated a large-scale case–control study of RCC in 1986 to
address the relationship between sustained use of analgesics and
RCC risk. This report describes in detail our findings with respect
to individual classes of analgesics by formulation.
MATERIALS AND METHODS
The study design and data collection have been described previ-
ously (Yuan et al, 1998a). In brief, the population-based cancer
registry of Los Angeles County identified 1724 non-Asian
patients, aged 25–74 years, with histologically confirmed RCC
between April 1986 and December 1994. Among these, 301
patients died before we could contact them or were too ill to be
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interviewed, and in 147 instances, the physician or patient refused
to cooperate. Thus, we interviewed 1276 patients (74% of all
eligible patients).
For each interviewed patient, we employed a standard algorithm
to recruit a control who was matched to the patient on sex, date of
birth (within 5 years), race and neighbourhood of residence at the
time of cancer diagnosis. If a matched control could not be identi-
fied, the case was dropped from the study. Seventy-two cases were
excluded from the study because of lack of matched controls. We
completed in-person interviews on 1204 control subjects.
In-person, structured interviews were conducted in subjects’
homes. The questionnaire requested information up to 2 years
prior to the diagnosis of cancer for cases and 2 years prior to diag-
nosis of cancer of the index case for matched controls. The ques-
tionnaire requested information on demographic characteristics,
height and weight, lifetime use of tobacco and alcohol, usual adult
dietary habits, lifetime occupational history, prior medical condi-
tions and prior use of medications.
We explicitly listed 44 over-the-counter and 33 prescription
brand-name analgesics in the questionnaire (see Appendix). These
brand-named drugs represent all common analgesics marketed in
the USA since the 1950s. A picture album of the listed drugs was
available to the respondents to assist in their recall of their usage.
For each of the listed brand-name analgesics, we first asked the
subjects whether they had ever taken the drug 20 or more times
over their lifetime. If the answer was no, the subject was defined as
a ‘non-user’. Otherwise, the subjects was further asked if they had
ever taken the drug two or more times a week for 1 month or
longer. If the answer was no, subjects were classified as ‘irregular
user’. Otherwise, subjects were defined as ‘regular user’ and
further asked about the ages at first and last use, duration of use,
usual frequency and dosage of use, and the primary reason for
such use. Aside from the 77 brand-name analgesics listed, the
subjects were asked if they had taken any other analgesics regu-
larly. If the answer was yes, the names of the analgesic drugs were
recorded, along with ages at first and last use, duration of use,
usual frequency and dosage of use, and the primary reason for use
were similarly asked.
At the end of the interview, subjects were asked to give permis-
sion for us to contact all physicians who had prescribed analgesics
to them. We attempted to contact all such physicians to validate
the self-reported information on use of prescription analgesics,
which included the name, dates and total months of use for every
analgesic drug being prescribed.
The formulations of the listed analgesics as well as those volun-
teered by study subjects were established through numerous phar-
maceutical sources, including the annually updated Physician’s
Desk Reference. Each active ingredient of brand-name analgesics
was classified according to formulation as follows: aspirin, non-
aspirin NSAID, acetaminophen, phenacetin and other. Similarly,
each active ingredient of non-aspirin NSAID was further classified
as propionic acid (such as ibuprofen and naproxen), acetic acid
(such as indomethacin and sulindac), salicylic acid and ‘other’.
Age-specific exposure to a given drug was estimated from a
subject’s reported dose and duration of use at that age. Lifetime
cumulative exposure (g) to a specific class of analgesics (such as
aspirin) was computed by summing individual age-specific expo-
sures across all ages and all brand-name drugs containing the
active ingredient of interest. Lifetime cumulative exposure to all
analgesics was computed by summing the cumulative exposures
for aspirin, non-aspirin NSAID, acetaminophen, phenacetin and
other analgesics. The average monthly dose (g) was calculated
as lifetime cumulative dose divided by total months of use.
Cumulative exposures and average monthly doses among regular
users were grouped into quartiles according to their distributions
among control subjects.
Data were analysed by standard matched-pair methods
(Breslow and Day, 1980). Conditional logistic regression models
were used to examine the relationship between analgesic use and
RCC risk with adjustment for other risk factors identified in the
Table 1 Regular use of different subclasses of analgesics in relation to risk of renal cell carcinoma
Regular usea Maximum weekly dose (g)b
< 2 2 –< 4 4 –< 8 8+
Aspirin
Cases/controls 413/323 98/118 102/81 99/63 105/56
ORc 1.6g 1.1 1.6g 2.0g 2.4g
ORd (95% CI) 1.5 (1.2–1.8) 1.1 (0.8–1.6) 1.5 (1.1–2.1) 1.7 (1.2–2.5) 1.9 (1.3–2.8)
Non-aspirin NSAID
Cases/controls 235/189 90/83 58/41 37/32 38/21
ORc 1.6g 1.3 1.8g 1.4 2.3g
ORd (95% CI) 1.4 (1.1–1.8) 1.3 (0.9–1.9) 1.5 (1.0–2.3) 1.3 (0.8–2.3) 1.9 (1.1–3.5)
Acetaminophen
Cases/controls 300/209 67/66 63/47 83/57 79/36
ORc 1.9g 1.3 1.8g 1.9g 2.8g
ORd (95% CI) 1.7 (1.3–2.1) 1.3 (0.9–1.9) 1.7 (1.1–2.6) 1.8 (1.2–2.6) 2.1 (1.3–3.3)
Phenacetin
Cases/controls 86/55 41/37 22/6 23/12e
ORc 2.0g 1.4 4.3g 2.2f –
ORd (95% CI) 1.9 (1.3–2.7) 1.3 (0.8–2.2) 4.1 (1.5–10.8) 2.3 (1.0–5.0)
aDefined as two or more times a week for 1 month or longer. bThe sum may be slightly less than the total number of users due to the exclusion of subjects with
missing values. cORs as compared to non- or irregular users of analgesics (616 cases, 744 controls) after adjustment for level of education. dFurther adjusted
for usual body mass index (kg m–2), history of hypertension (yes, no), average number of cigarettes smoked per day, current smoking status (smoker,
non-smoker) and regular use of amphetamines (yes, no). eIncluded four cases and two controls whose maximum weekly dose of phenacetin was 8 or more g.
fTwo-sided P < 0.05 and g two-sided P < 0.01, test for OR = 1.0.544 M Gago-Dominguez et al
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present study (obesity, history of hypertension, cigarette smoking
and regular use of amphetamines) (Yuan et al, 1998a, 1998b).
Population attributable risks were computed as described in
Breslow and Day (1980). All P-values quoted are two-sided.
RESULTS
The mean age of the patients at diagnosis of RCC was 58.8 years.
Most patients were non-Hispanic whites (n = 1028) with the
remaining being Hispanic whites (n = 107) and African-Americans
(n = 69). On average, RCC patients had lower level of education
than controls. The odds ratio (OR) for RCC was 0.6 (95% confi-
dence interval (CI) = 0.5–0.7) for those who had attended college
(13 years or more of schooling) compared with those who had a
high school education or lower. Thus, all ORs presented below
were adjusted for level of education (high school or less, college or
above).
Relative to lifetime non-users of analgesics, irregular users
of analgesics exhibited no increase in risk of RCC (OR = 1.0,
95% CI = 0.7–1.4). On the other hand, regular users of analgesics
(at least twice a week for 1 month or longer) showed a statistically
significant increase in risk relative to non- or irregular users
(OR = 1.6, 95% CI = 1.4–1.9). Among regular users, mean
duration of lifetime use was significantly longer in cases than in
controls (96 months vs 81 months, P = 0.035).
Table 1 presents the analgesic–RCC relationship separately for
each of the four major formulation classes of analgesics – aspirin,
non-aspirin NSAID, acetaminophen and phenacetin. There was a
statistically significant elevation in risk of RCC associated with
use of each of the four chemical classes of analgesics. Overall risk
was very similar for phenacetin and acetaminophen formulations.
Overall risk was also similar for aspirin and non-aspirin NSAID
classes. The latter two risk estimates were modestly lower than for
phenacetin and acetaminophen compounds, but the two sets of
risks were not statistically different from each other. Within each
class of analgesics, there was generally increasing risk with
increasing level of exposure, irrespective of whether exposure was
defined as maximum weekly dose (see Table 1), average monthly
dose, maximum number of pills per day, or total intake over life-
time (data not shown). Adjustment for other risk factors for RCC
did not materially alter any of the analgesic–cancer associations.
Results in men were numerically and statistically comparable to
those in women. We also conducted pair-wise comparisons of risks
associated with per unit gram intake of aspirin, non-aspirin
NSAID and acetaminophen with adjustment for the level of intake
of other analgesics. No differences were observed.
We further examined the risk of RCC from non-aspirin NSAIDs
according to their organic acid formulations. All formulations of
non-aspirin NSAID examined were positively associated with
RCC risk: the ORs after adjustment for other risk factors were
1.3 (95% CI = 1.0–1.7), 1.5 (95% CI = 1.0–2.2) and 1.7 (95%
CI = 1.1–2.7) for propionic, salicylic and acetic acids respectively.
There were 159 cases and 133 controls who were exclusive
users of aspirin, 61 cases and 50 controls who were exclusive users
of non-aspirin NSAIDs, and 74 cases and 54 controls who were
exclusive users of acetaminophen. There were no exclusive users
of phenacetin due to the fact that all phenacetin-containing
analgesics consumed by study subjects also contained aspirin.
Table 2 Regular use of all analgesics in relation to risk of renal cell carcinoma
All analgesics Total Males Females
Ca/Co ORa ORb (95% CI) Ca/Co ORa ORb (95% CI) Ca/Co ORa ORb (95% CI)
Regular usec
No 616/744 1.0 1.0 420/498 1.0 196/246 1.0
Yes 588/460 1.6f 1.5 (1.3–1.8) 361/283 1.5f 1.4 (1.2, 1.8) 227/177 1.8f 1.7 (1.2–2.3)
Total consumption
over lifetime (g)d
< 60 115/112 1.3 1.3 (1.0–1.8) 79/71 1.3 1.5 (1.0–2.1) 36/41 1.2 1.2 (0.7–2.0)
60 –< 312 125/102 1.5f 1.5 (1.1–2.0) 82/66 1.5e 1.5 (1.0–2.2) 43/36 1.6 1.6 (0.9–2.6)
312 –< 1287 131/112 1.6f 1.4 (1.0–1.9) 87/75 1.5e 1.2 (0.8–1.7) 44/37 1.9e 1.9 (1.1–3.2)
1287+ 205/121 2.2f 1.9 (1.4–2.5) 107/64 2.0f 1.7 (1.2–2.5) 98/57 2.5f 2.1 (1.4–3.3)
Average monthly dose (g)d
< 5 90/107 1.1 1.1 (0.8–1.6) 61/68 1.1 1.2 (0.8–1.7) 29/39 1.0 1.0 (0.5–1.8)
5 –< 10 138/130 1.3 1.2 (0.9–1.6) 99/88 1.3 1.2 (0.9–1.8) 39/42 1.2 1.1 (0.6–1.9)
10 –< 20 121/96 1.6f 1.6 (1.1–2.2) 76/60 1.6e 1.5 (1.0–2.3) 45/36 1.6 1.6 (0.9–2.8)
20+ 227/114 2.6f 2.2 (1.6–2.9) 119/60 2.3f 2.0 (1.3–2.9) 108/54 2.9f 2.5 (1.6–3.9)
Maximum weekly dose (g)d
< 2 115/136 1.1 1.1 (0.8–1.5) 81/88 1.2 1.2 (0.8–1.7) 34/48 1.0 1.0 (0.6–1.7)
2 –< 4 136/120 1.3e 1.3 (1.0–1.8) 96/80 1.4 1.3 (0.9–1.8) 40/40 1.2 1.3 (0.7–2.2)
4 –< 8 134/99 1.7f 1.6 (1.2–2.2) 81/62 1.6f 1.6 (1.1–2.4) 53/37 1.9f 1.6 (1.0–2.7)
8+ 195/93 2.7f 2.3 (1.7–3.1) 100/46 2.5f 2.0 (1.3–3.1) 95/47 3.0f 2.6 (1.7–4.1)
Maximum No. of pills
per dayd
< 1 47/57 1.1 1.1 (0.7–1.7) 34/34 1.2 1.3 (0.7–2.2) 13/23 0.9 0.9 (0.4–1.8)
1 187/187 1.2 1.2 (0.9–1.6) 130/129 1.2 1.2 (0.9–1.6) 57/58 1.3 1.2 (0.7–2.0)
2 118/91 1.7f 1.6 (1.1–2.2) 72/55 1.7f 1.5 (1.0–2.4) 46/36 1.7e 1.6 (0.9–2.7)
3+ 228/113 2.6f 2.2 (1.7–2.9) 122/58 2.6f 2.1 (1.4–3.1) 106/55 2.7f 2.4 (1.6–3.7)
aAdjusted for level of education. bFurther adjusted for usual body mass index (kg m–2), history of hypertension (yes, no), average number of cigarettes smoked
per day, current smoking status (smoker, non-smoker) and regular use of amphetamines (yes, no). cDefined as two or more times a week for 1 month or longer.
dThe sum may be slightly less than the total number of users due to the exclusion of subjects with missing values. eTwo-sided P < 0.05 and ftwo-sided
P < 0.01, test for OR = 1.0Analgesics and renal cell carcinoma 545
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Compared with non- or irregular users of analgesics, increased
risks of RCC were observed among exclusive users of aspirin
(OR = 1.4; 95% CI = 1.1–1.9; P = 0.01), non-aspirin NSAID
(OR = 1.5; 95% CI = 1.0–2.2; P = 0.06), and acetaminophen
(OR = 1.6; 95% CI = 1.1–2.4; P = 0.03) after adjustment for other
risk factors. Prescription analgesics frequently contain narcotic
analgesics (such as codeine, propoxyphene, oxycodone and
meperidine). There were only a few study subjects (six cases,
seven controls) who exclusively used narcotic analgesics and no
increased risk of RCC relative to non- or irregular users of anal-
gesics was observed (OR = 1.0; 95% CI = 0.3–3.2).
There were 288 cases and 216 controls who used more than one
chemical class of analgesics regularly. These regular users of
‘mixed analgesics’ exhibited comparable cancer risk level as users
of single classes of analgesics (OR = 1.5, 95% CI = 1.2–1.9 when
compared with non- or irregular users of analgesics).
Results in Table 1 indicated that RCC risk associated with per
unit gram intake of aspirin consumed was comparable to that of
acetaminophen, phenacetin and non-aspirin NSAIDs. Since it is
biologically plausible that the carcinogenic potencies of analgesics
are similar across the various formulations and this concept is
supported by empirical data, we constructed overall analgesic
exposure indices by summing the formulation-specific indices
across categories of formulation. Such a cumulative exposure
index also provides a reliable estimate of the contribution of anal-
gesics categorically to RCC risk. Table 2 presents the results of
these summary indices of analgesic use – total lifetime intake (g),
average monthly dose (g), maximum weekly dose (g) and
maximum number of pills per day. Independent of the exposure
index under examination, there was statistically significant
increase in cancer risk with increasing level of exposure. The risk
associated with the highest level of exposure was at least 2.2-fold
relative to no exposure. Similar results were obtained when
adjustment was made for other risk factors for RCC. Results were
similar between men and women (Table 2).
We examined the analgesic–RCC association according to the
reason for drug use. Significantly elevated risks were observed
among all regular users of analgesics except those who took anal-
gesics for cardiovascular disease prevention (OR = 1.0; 95% CI =
0.7–1.6), or for cold, flu or allergy (OR = 1.1; 95% CI = 0.7–1.6).
Subjects who took analgesics for cold, influenza or allergy usually
used relatively low doses for short periods of time: the mean life-
time cumulative dose among cases was 0.8 kg, which was only
15% of that (5.5 kg) among cases who used the drug to alleviate
headache.
Among regular users of analgesics who took the drug for the
sole reason of cardiovascular health (all of them were exclusive
users of aspirin), no increase in risk of RCC was observed among
those taking 325 mg or less of aspirin per day (OR = 0.9; 95%
CI = 0.6–1.4). On the other hand, there was a duration-dependent
increase in risk among those taking higher doses of aspirin for this
reason, although none of the ORs reached statistical significance
(Table 3). This set of results was confirmed when we repeated the
analysis on the larger set of subjects comprising all exclusive users
of aspirin regardless of reason for use. Among those taking
325 mg or less of aspirin per day, no increase in risk of RCC was
observed regardless of duration of use (up to 10 or more years). In
contrast, those taking higher doses per day exhibited a statistically
significant 2.5-fold risk relative to non- and irregular users of anal-
gesics. Furthermore, this elevation in risk was duration-dependent
(Table 3).
There were 578 individual prescription analgesics reported by
cases and 384 by controls. Among cases, we received responses
from physicians to 195 (34%) of these self-reported prescription
analgesics, and 85 (44%) showed agreement on brand name
between physician records and self-reported information. Among
controls, the corresponding figures were 139 (36%) and 59 (42%)
respectively.
DISCUSSION
To our knowledge, the present study is the largest case–control
study of RCC ever conducted in a single, geographically defined
study population. The large sample size of this study allows for the
effects of major classes of analgesics (acetaminophen, aspirin,
non-aspirin NSAID and phenacetin) to be compared with a reason-
able degree of certainty. Our data demonstrate that sustained use of
analgesics is a significant, independent risk factor for RCC, and
that the elevation in risk extends across major formulation
categories including aspirin, other NSAIDs, acetaminophen and
phenacetin.
Table 3 Average daily dose and duration of use of aspirin and risk of renal cell carcinoma
≤ 325a mg per day ³ 326 mg per day
Cases Controls ORb ORc (95% CI) Cases Controls ORb ORc (95% CI)
Aspirin only for cardiovascular
disease prevention 40 50 0.9 0.9 (0.6–1.4) 14 9 2.0 2.0 (0.8–5.1)
Duration of use (years)
< 5 20d 27 0.8 0.8 (0.4–1.4) 4 4 1.4 1.7 (0.4–7.8)
³ 5 19 23 1.0 1.0 (0.5–1.9) 10 5 2.6 2.3 (0.7–7.4)
Aspirin only for any reason 77 91 1.0 1.0 (0.7–1.5) 82 40 2.7f 2.5 (1.6–3.9)
Duration of use (years)
< 5 41d 50 1.0 1.0 (0.6–1.5) 45 27 2.2f 2.0 (1.2–3.4)
5 –< 10 22 26 1.1 1.0 (0.5–1.9) 14 7 2.9e 3.0 (1.1–8.2)
³ 10 12 15 1.1 1.3 (0.5–3.0) 23 6 4.9f 4.3 (1.6–11.3)
aOne regular strength aspirin contains 325 mg of aspirin. bORs as compared to non- or irregular users of analgesics (616 cases, 744 controls) after adjustment
for level of education. cORs were further adjusted for usual body mass index (kg m–2), history of hypertension (yes, no), average number of cigarettes smoked
per day, current smoking status (smoker, non-smoker) and regular use of amphetamines (yes, no). dThe sum was slightly less than the total number of users
due to the exclusion of subjects with missing values. eTwo-sided P < 0.05 and † two-sided P < 0.01, test for OR = 1.0.546 M Gago-Dominguez et al
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We were concerned that recall bias might explain the observed
analgesic–RCC associations. We were able to indirectly address
this issue through an analysis of an ongoing parallel study of
bladder cancer in Los Angeles, which shared the same set of
questions on medication use as the present study. Furthermore, the
same team of interviewers was used in both studies. A total of
1379 bladder cancer patients and an equal number of age-, sex-
and race-matched neighbourhood controls were included in this
analysis. There were 498 (36%) bladder cancer patients and 537
(39%) control subjects who had used analgesics regularly. The risk
of bladder cancer associated with regular use of analgesics was 0.9
(95% CI = 0.8–1.1).
Besides the current study, there is one other large-scale study
that has addressed the analgesic–RCC association. This multi-
centre, international case–control study involved 1732 RCC
patients and 2309 controls (McCredie et al, 1995). The investiga-
tors noted no increase in risk of RCC among regular users of
phenacetin, acetaminophen and salicylates (mainly aspirin). Thus,
results of this study are in rather stark contrast to those reported
here. We have no clear explanation to these disparate findings.
However, the design of our study and that of McCredie et al (1995)
differs in several respects. Our target population was a single,
geographically defined population consisting primarily of a single
racial-ethnic group (non-Hispanic whites). All interviews were
conducted by a single team of four interviewers and virtually all
matched case–control pairs were interviewed by the same inter-
viewer. Extensive research was conducted in the compilation of
the brand-name analgesic list to ensure comprehensive coverage of
the relevant time period. A picture album of the explicitly named
analgesics was developed and made available to the respondents to
aid in their recall. Finally, there was an attempt to validate all self-
reported usage of prescription analgesics with physician records.
Although only one-third of all self-reported prescription analgesic
usage were successfully traced, we observed no difference in the
rate of concordance between physician records and self-reports
between the case and the control groups (44% and 42% respec-
tively). In contrast, the multicentre study included subjects from
five centres in four countries with varying patterns of analgesic
use. Country-specific brand-names of analgesics were compiled,
but different criteria were used to construct the drug lists across the
various centres. No visual aid was offered to the respondents
during the interviews to assist in recall and there was no attempt to
validate self-reported usage of prescription medications.
Phenacetin has been found to induce renal cell adenomas and
RCC in rodents (Johansson, 1981; Nakanishi et al, 1982). A
number of case–control studies have shown regular use of
phenacetin to be associated with a 1.5- to 6.0-fold increased risk of
RCC (McLaughlin et al, 1985; Maclure and MacMahon, 1985;
McCredie et al, 1988; Kreiger et al, 1993; Mellemgaard et al,
1994). The present study confirms that sustained use of phenacetin
is a risk factor for RCC, conferring a two-fold excess risk among
regular users of this drug. Phenacetin has been absent from all
drugs manufactured in the USA since 1987.
Acetaminophen, a major metabolite of phenacetin, can induce
renal proximal tubular necrosis (Emeigh Hart et al, 1991) and
increase the incidence of kidney preneoplastic lesions and renal
adenomas in carcinogen-treated rodents (Tsuda et al, 1984).
Several case–control studies of RCC have investigated the specific
relationship with acetaminophen exposure. Results are mixed.
Two studies (McCredie et al, 1993; Derby and Jick, 1996) have
reported dose-dependent, positive associations while others found
no association (McLaughlin et al, 1985; Kreiger et al, 1993;
McCredie et al, 1995; Rosenberg et al, 1998). The present study
demonstrates that sustained use of acetaminophen is associated
with a two-fold risk of RCC, with a statistically significant
dose–response relation after adjustment for phenacetin use.
Aspirin in therapeutic doses can be nephrotoxic, producing
renal tubular damage, papillary necrosis and chronic interstitial
nephritis (Prescott, 1982). Experimental models have shown that
chronic administration of aspirin can induce progressive toxic
damage to the proximal convoluted tubules, renal papillary
necrosis and chronic interstitial nephritis in rodents (Plummer
et al, 1975; Prescott, 1982; Burrell et al, 1991). Human data
regarding carcinogenesis are relatively sparse. One cohort study of
a retirement community in Southern California found that daily
aspirin use was associated with a sixfold risk of kidney cancer in
men and a twofold risk in women (Paganini-Hill et al, 1989). A
few case–control studies have reported use of aspirin to be related
to an increased risk of RCC (Asal et al, 1988; Mellemgaard et al,
1994) while others found no such association (McLaughlin et al,
1985; McCredie et al, 1995). In the present study, exclusive users
of aspirin who took dosages higher than 325 mg per day were
clearly at an increased risk of RCC.
Experimental models have shown that chronic administration of
various non-aspirin NSAIDs can induce papillary necrosis and
chronic interstitial nephritis in rodents (Prescott, 1982). In addi-
tion, phenylbutazone, an NSAID, has been shown to induce
adenomas and RCC in treated rats (Kari et al, 1995). In humans,
acute tubular necrosis, papillary necrosis and interstitial nephritis
have been histologically or radiographically confirmed in patients
consuming therapeutic doses of non-aspirin NSAID (Adams et al,
1986; Segasothy et al, 1994). Due to the novelty of this class of
compounds, no prior studies have investigated their carcinogenic
potential in humans. The present study shows that sustained use of
non-aspirin NSAID is related to RCC development in a dose-
dependent manner.
Interestingly, our data implicate somewhat comparable levels
of carcinogenic potency across the major classes of analgesics
(aspirin, non-aspirin NSAID, phenacetin and acetaminophen)
despite their chemical and pharmacological differences. The
current findings suggest a common pathway in the oncogenic
potential of these chemically diverse drugs. One such possible
pathway is the shared ability of these drugs to induce renal damage
leading to increased cell proliferation at the target site, a recog-
nized mechanism of increased cancer risk in humans (Henderson
et al, 1991). Aspirin, non-aspirin NSAID, phenacetin and aceta-
minophen used alone or in combination have been reported to be
associated with chronic nephropathy, chronic renal failure or end-
stage renal disease in several case–control studies (Pommer et al,
1989; Sandler et al, 1989; 1991; Perneger et al, 1994). In vivo and
in vitro rodent models have shown that aspirin, non-aspirin
NSAID and acetaminophen undergo in situ metabolic activation in
the kidney with subsequent covalent binding of the highly reactive
metabolites to tissue/microsomal proteins, leading to tubular
necrosis (Mitchell et al, 1977; McMurtry et al, 1978; Kyle and
Kocsis, 1985; Emeigh Hart et al, 1991). In an animal model of
chronic analgesic nephropathy in which renal papillary necrosis
was induced by the administration of bromoethylamine 2-hydro-
bromide in male rats, Gobé and Axelsen (1991) demonstrated
increased cell proliferation in the tubular epithelium and in the
interstitium of the renal cortex in kidneys that exhibited renal
papillary necrosis.Analgesics and renal cell carcinoma 547
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Our data suggest that chronic intake of one regular-strength
aspirin (325 mg) or less a day for cardiovascular health does not
lead to an increased risk of RCC whereas higher daily doses do so.
It is important to note that controlled trials have shown that
325 mg of aspirin every two days in disease-free subjects results in
about a 40% decrease in risk of a first myocardial infarction
(Steering Committee of the Physicians Health Study Research
Group, 1989) and that doses higher than 325 mg per day in
patients with a history of myocardial infarction do not result in
greater protection from a second myocardial infarction compared
to lower dosages (Antiplatelet Trialists’ Collaboration, 1994).
A number of studies have shown that regular use of aspirin or
non-aspirin NSAID is associated with a 40–50% reduction in
colorectal cancer (Giovannucci et al, 1995). NSAIDs inhibit the
synthesis of COX-2-derived prostaglandins which are implicated in
colon carcinogenesis (Eberhart et al, 1994). It is important to note
that NSAID-induced renal damage is believed to be due to the inhi-
bition of COX-1-derived renal prostaglandins which are important
for renal homeostasis (Sabatini, 1996). Ruffin et al (1997) noted that
experimental human subjects ingesting no more than 324 mg of
aspirin per day for 14 days exhibited statistically significant, 20%
reduction in colorectal mucosal prostaglandin E2 and F2a.
There is epidemiological evidence that regular intake of aspirin
or other forms of NSAID is protective against Alzheimer’s disease
and multi-infarct dementia, which constitutes the second
commonest type of dementia among elderly people in the USA
(Meyer et al, 1989). A large number of case–control and cohort
studies have shown that use of NSAID is associated with a
30–50% reduction in risk of Alzheimer’s disease (McGeer et al,
1996). In a randomized trial involving multi-infarct dementia
patients, those taking one regular-strength (325 mg) aspirin daily
for 3 years showed statistically significant improvement in both
cerebral perfusion values and cognitive performance scores
relative to the control group at each of the three annual follow-up
evaluations (Meyer et al, 1989).
To place the risks (RCC) and benefits (heart disease, colorectal
cancer, Alzheimer’s disease) of regular use of NSAID in an
appropriate perspective, one needs to consider the comparative
incidence of the aforementioned health outcomes in the USA.
While RCC is a relatively rare malignancy (six per 100 000 non-
Hispanic whites) (Yu et al, 1999), the corresponding rates for
colorectal cancer, Alzheimer’s disease and fatal ischaemic heart
disease are 44, 95 and 204 per 100 000 respectively (Kokmen et al,
1993; Liu et al, 1998; National Center for Health Statistics, 1996).
Our data provide no evidence that ingestion of a regular strength
(325 mg) aspirin a day even for as long as 10 years leads to any
increased risk of RCC. Given that there is no evidence of further
protection from cardiovascular disease, colorectal cancer or
Alzheimer’s disease development with a daily aspirin dose higher
than 325 mg per day, we would recommend a dosage of 325 mg
aspirin per day or less for preventive health purposes.
In summary, this large-scale, population-based case–control
study strongly implicates chronic use of analgesics as a causal
factor in RCC development. We estimate that 18% (15% in men,
25% in women) of RCC in Los Angeles County, California can be
attributed to this iatrogenic exposure.
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APPENDIX
Over-the counter analgesics
APC, ASA compound, Bancaps, Momentum, Empirin compound
without codeine, regular aspirin, extra strength aspirin, buffered
aspirin, arthritis strength Bufferin, regular strength Tylenol, extra
strength Tylenol, Cotylenol, generic acetaminophen, regular
Anacin, arthritis pain formula Anacin, Anacin-3 regular strength
or aspirin-free Anacin, Anacin-3 maximum strength or aspirin-
free Anacin, Excedrin, Excedrin P.M. or aspirin-free Excedrin,
extra strength Excedrin, regular strength Datril, extra strength
Datril, Advil, Nuprin, Cama, Comtrex, Coricidin, Dristan or
advanced formula Dristan, 4-way cold tablet, Nyquil, Robitussin
night relief, Sine-aid, Sinutab, Triaminicin, Bromoseltzer, Midol,
Pamprin, Vanquish, Alka seltzer, Tempra, Goody’s headache
powders, Stanbank, BC power or tablets and Doan’s pills.
Prescription analgesics
Clinoril, Motrin, Anaprox, Feldene, Empirin with codeine, aspirin
with codeine, APC with codeine, Tylenol with codeine, Tylox,
Darvocet, Darvon, Darvon compound, Indocin, Fiorinal, Percocet-
5, Percodan, phenylbutazone (Azolid, Azolid-A, Butazolidin,
Butazolidin-alka), Norgesic or Norgesic forte, Phenaphen,
Arthralgen, Midrin, Wigraine, Buff-a-comp, Nalfon, Repan,
Naprosyn, Valadol, Medache, Equagesic, Percogesic, Synalgos,
Talwin or Talwin 50 and Talwin compound.
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